Date of publication: July 13, 2021 Evidence Summary: Two-dose Inactivated Polio Vaccine (IPV) versus One- dose IPV for the prevention of Poliomyelitis Advisory for Appeals on Preliminary Recommendation: https://bit.ly/CallforAppeals_2DoseIPVPNF HTAC Recommendation Review:
Sputnik V, Pfizer – BioNTech, Janssen, AstraZeneca (June Reassessments)
COVID-19 VACCINES EVIDENCE SUMMARY HTAC PRESS RELEASE In fulfilment of its mandate of promoting evidence-informed health policy and decision-making, the Health Technology Assessment Council (HTAC) continues to update its assessments of health technologies. In light of emerging real world effectiveness and real world safety data, the HTAC considers new evidence in updating recommendations on the continue reading : Sputnik V, Pfizer – BioNTech, Janssen, AstraZeneca (June Reassessments)
COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the Prevention of COVID-19
Date of publication: May 28, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine Moderna. This assessment follows the continue reading : COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the Prevention of COVID-19
Janssen Ad26.COV2.S (COVID-19) Vaccine for the Prevention of COVID-19
Date of publication: April 30, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine Janssen. This assessment follows the continue reading : Janssen Ad26.COV2.S (COVID-19) Vaccine for the Prevention of COVID-19
Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the Prevention of COVID-19
Date of publication: April 12, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine Gamaleya. This assessment follows the continue reading : Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the Prevention of COVID-19